Document is current
Any future updates will be listed below
-
Authors
Mathieu, Chantal https://orcid.org/0000-0002-4055-5233
Martens, Pieter-Jan
Vangoitsenhoven, Roman https://orcid.org/0000-0003-3523-669X
- License Information
-
More Information
Article History
Accepted: 15 July 2021
First Online: 17 August 2021
Competing interests
: C.M. serves or has served on the advisory panel for Novo Nordisk, Sanofi, Merck Sharp and Dohme Ltd., Eli Lilly and Company, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Insulet and Zealand Pharma. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for C.M. from Medtronic, Novo Nordisk, Sanofi and ActoBio Therapeutics; C.M. serves or has served on the speakers’ bureau for Novo Nordisk, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, AstraZeneca and Novartis. Financial compensation for these activities has been received by KU Leuven. R.V. serves or has served on the speakers’ bureau for Novo Nordisk, Sanofi, Boehringer Ingelheim, AstraZeneca and Mundipharma. Financial compensation for these activities has been received by KU Leuven. P.-J. M. declares no competing interests.
